Amgen Inc. Debt Securities, Available-for-sale, Current
Amgen Inc. (AMGN) had Debt Securities, Available-for-sale, Current of $0 as of 2023-12-31, per its 10-K filed 2024-02-14.
Discontinued › Balance Sheet › Assets › Assets, Current › Short-Term Investments
us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent · last filed 2024-02-14
- 2023-12-31: Debt Securities, Available-for-sale, Current $0.00.
- 2023-09-30: Debt Securities, Available-for-sale, Current $0.00.
- 2023-06-30: Debt Securities, Available-for-sale, Current $0.00.
- 2023-03-31: Debt Securities, Available-for-sale, Current $1.00M.
| Period end | Debt Securities, Available-for-sale, Current |
|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-02-14 |
| 2023-09-30 | $0.00 10-Q · filed 2023-10-31 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-04 |
| 2023-03-31 | $1.00M 10-Q · filed 2023-04-28 |
| 2022-12-31 | $1.68B 10-K · filed 2024-02-14 |
| 2022-09-30 | $1.98B 10-Q · filed 2022-11-04 |
| 2022-06-30 | $1.98B 10-Q · filed 2022-08-05 |
| 2022-03-31 | $16.00M 10-Q · filed 2022-04-28 |
| 2021-12-31 | $48.00M 10-K · filed 2023-02-09 |
| 2021-09-30 | $952.00M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $1.45B 10-Q · filed 2021-08-04 |
| 2021-03-31 | $4.45B 10-Q · filed 2021-04-28 |
| 2020-12-31 | $4.38B 10-K · filed 2022-02-16 |
| 2020-09-30 | $3.27B 10-Q · filed 2020-10-29 |
| 2020-06-30 | $2.28B 10-Q · filed 2020-07-29 |
| 2020-03-31 | $325.00M 10-Q · filed 2020-05-01 |
| 2019-12-31 | $2.87B 10-K · filed 2021-02-09 |
| 2019-09-30 | $9.44B 10-Q · filed 2019-10-30 |
| 2019-06-30 | $16.23B 10-Q · filed 2019-07-31 |
| 2019-03-31 | $18.94B 10-Q · filed 2019-05-01 |
| 2018-12-31 | $22.36B 10-K · filed 2020-02-12 |
| 2018-09-30 | $17.96B 10-Q · filed 2018-10-31 |
| 2018-06-30 | $19.26B 10-Q · filed 2018-07-27 |
| 2017-12-31 | $37.88B 10-K · filed 2019-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |